Corcept Stock Soars 40% on Early FDA Cancer Drug Approval

Corcept Therapeutics Stock Surges on FDA Approval

Corcept Therapeutics (NASDAQ:CORT) shares surged by 40% on Wednesday following the U.S. Food and Drug Administration's approval of its drug, relacorilant, marketed as Lifyorli. The drug is approved in combination with nab-paclitaxel for treating adults with specific types of advanced ovarian cancer.

Details of the Regulatory Milestone

The FDA's decision, which arrived 2.5 months ahead of its goal date, was based on positive results from the multicenter ROSELLA clinical trial. This study involved 381 patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The approval applies to patients who have received one to three prior systemic treatments.

Clinical Data and Market Reaction

The ROSELLA trial demonstrated that the combination therapy improved median progression-free survival to 6.5 months compared to 5.5 months for nab-paclitaxel alone. Overall survival also increased to 16 months versus 11.9 months for the single agent. This strong clinical data fueled significant investor confidence, leading to the substantial rally in Corcept's stock price.

Summary and Outlook

The early FDA approval and compelling clinical results for relacorilant represent a major achievement for Corcept Therapeutics, significantly boosting its oncology portfolio. Market focus will now shift to the drug's commercial launch and adoption by clinicians.

FAQ

Q: What drug did the FDA approve for Corcept Therapeutics?
A: The FDA approved relacorilant, brand name Lifyorli, to be used in combination with nab-paclitaxel for certain types of advanced ovarian cancer.

Q: How much did Corcept's stock increase after the announcement?
A: Corcept Therapeutics (CORT) stock surged by 40% after the news of the FDA approval was released.

Source: Investing.com